Zai Lab Limited — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021; filed March 1, 2022. This is an annual report, not a standalone fourth-quarter filing. Financial figures are in U.S. dollars unless stated otherwise.
Business context
Zai Lab is a Cayman Islands holding company with substantial operations in Greater China and the United States. It develops and commercializes therapies in oncology, autoimmune disorders, infectious diseases and neuroscience. At year-end, it had four commercialized products—ZEJULA, Optune, QINLOCK and NUZYRA—and a broad pipeline, including 12 programs described as late-stage in the business overview. Revenue was principally from product sales in Greater China.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $144.3 million | $49.0 million |
| Net product revenue | $144.1 million | $49.0 million |
| Cost of sales | $52.2 million | $16.7 million |
| Gross profit / gross margin | $91.9 million / 63.8% | $32.2 million / 65.8% |
| Research and development expense | $573.3 million | $222.7 million |
| Selling, general and administrative expense | $218.8 million | $111.3 million |
| Operating loss | $700.1 million | $301.8 million |
| Net loss | $704.5 million | $268.9 million |
| Operating cash used | $549.2 million | $216.1 million |
- Revenue grew approximately 195%. ZEJULA contributed $93.6 million, Optune $38.9 million, QINLOCK $11.6 million and NUZYRA approximately $3,000.
- Cost of sales rose partly due to higher product costs and royalties, including an $8.0 million ZEJULA sales milestone. Net product revenue included $46.1 million of rebates and sales returns, including $29.5 million of ZEJULA-related compensation following NRDL inclusion.
- R&D expense increased $350.6 million; $384.1 million of licensing fees were recorded, mainly reflecting upfront and milestone payments. The increase also reflected higher personnel and clinical-trial costs. SG&A rose with commercial expansion, staffing and public-company costs.
- At December 31, cash and cash equivalents were $964.1 million, short-term investments $445.0 million and restricted cash $0.8 million. Total current assets were $1.50 billion; current liabilities were $192.9 million. Total liabilities were $230.0 million, including operating lease liabilities. Short-term borrowings had been repaid in 2020; the filing does not report material year-end debt borrowings.
- Financing activities provided $820.2 million in cash, primarily from equity offerings; investing activities provided $250.0 million, largely reflecting net short-term investment maturities. Cash, cash equivalents and restricted cash increased $522.0 million during 2021.
- Shares issued and outstanding increased from 87.8 million at year-end 2020 to 95.5 million at year-end 2021. The company also issued shares as part of the efgartigimod collaboration.
Fourth-quarter results and changes
In Q4 2021, net product revenue was $44.0 million versus $15.1 million in Q4 2020. Net loss was $211.8 million versus $76.5 million. Revenue growth reflected a larger commercial portfolio and higher sales, while quarterly losses were affected by elevated research and development and operating expenses. Q4 figures are unaudited quarterly data in the filing.
For the full year, ZEJULA and Optune sales increased, QINLOCK contributed $11.6 million following its 2021 launch, and NUZYRA received mainland China approval and launched in late December. NUZYRA’s full-year recognized product revenue was minimal. Losses widened substantially as the company expanded its pipeline and commercial operations, including large licensing charges.
Outlook, risks and unusual items
- Management stated that cash, cash equivalents and short-term investments available as of March 1, 2022 were expected to fund operating expenses and capital expenditure for at least the next 12 months after issuance of the financial statements. It also said additional funding would ultimately be needed to meet development objectives. No quantified revenue or profitability guidance was provided.
- Key commercial priorities included expanding ZEJULA uptake following first-line NRDL inclusion effective January 2022, increasing Optune adoption, and continuing QINLOCK and NUZYRA commercialization. The company anticipated continued substantial R&D and commercialization spending.
- Licensing commitments are substantial: the filing estimates up to approximately $5.59 billion in future contingent milestone payments across agreements, in addition to royalties. These payments depend on specified development, regulatory and commercial milestones and may not occur.
- Important risks include continuing losses and cash burn; dependence on four approved products and a small number of distributors; clinical, regulatory, manufacturing and supply-chain uncertainty; pricing and reimbursement pressure; and reliance on partners for many licensed assets.
- The company warned of legal and operational risks tied to mainland China, including evolving data security, human genetic resources and overseas-listing requirements, currency and cash-transfer restrictions, and uncertainty around regulatory interpretation. It had no VIE structure and said its Chinese subsidiaries held required business licenses and material permits.
- The filing highlighted U.S.-China audit oversight and possible Nasdaq delisting risk. Its risk discussion says the auditor was not subject to PCAOB inspection, while the audit report identifies Deloitte as PCAOB-registered; investors should verify the current inspection and listing status.
- Unusual items included the $384.1 million of R&D licensing fees, $14.6 million fair-value loss on the MacroGenics equity investment, and $46.1 million of product rebates and sales returns. No material legal proceedings were reported. The independent auditor issued unqualified opinions on the financial statements and internal controls; management also assessed internal controls as effective.
Important facts for investors to verify
- Product-level sales, net pricing and rebate assumptions—particularly ZEJULA’s NRDL effects—and whether revenue growth converts into improved gross margins and cash generation.
- The composition and timing of the $384.1 million licensing expense, and the potential cash, dilution and royalty burden of contingent collaboration commitments.
- Cash burn, liquidity runway and the assumptions behind management’s stated 12-month funding outlook; separately assess future financing and dilution needs.
- Pipeline milestones, trial outcomes and regulatory status, including the effect of the QINLOCK INTRIGUE Phase III result, which missed its primary endpoint in second-line GIST.
- Customer and distributor concentration, collection of receivables, and the impact of reimbursement and pricing policies on product demand.
- Current PCAOB inspection, HFCA Act and Nasdaq listing status, and any changes to Chinese data, cybersecurity, CSRC filing or cross-border cash-transfer requirements.